General Information of the Compound
Compound ID |
CP0036726
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compound Name |
(2R,3R,4S)-4-carbamimidamido-3-acetamido-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
Show/Hide
|
||||||||||||||||||
Synonyms |
GANA
(2R,3R,4S)-3-acetamido-4-(diaminomethylideneamino)-2-[(1R,2R)-1,2,3-trihydroxypropyl]-3,4-dihydro-2H-pyran-6-carboxylic acid
139110-80-8
4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid
4-Guanidino-Neu5Ac2en
4-Guanidino-NeueAc2en
4-guanidino-Neu5Ac2en
5-(acetylamino)-4-{[amino(imino)methyl]amino}-2,6-anhydro-3,4,5-trideoxy-D-glycero-D-galacto-non-2-enonic acid
5-Acetamido-2,6-anhydro-3,4,5-trideoxy-4-guanidino-D-glycero-D-galacto-non-2-enonic acid
AK163166
BAC-zanamivir
C12H20N4O7
CHEBI:50663
CHEMBL222813
DSSTox_CID_3749
DSSTox_GSID_23749
DSSTox_RID_77184
GANA
GANA (inhibitor)
GG 167
GG-167
GG167
GNA
GR 121167X
GR-121167X
GR121167X
HSDB 7437
L6O3XI777I
MODIFIED SIALIC ACID
Relenza
Relenza (TN)
UNII-L6O3XI777I
ZMR
ZNV
Zanamavir
Zanamivir
Zanamivir (Relenza)
Zanamivir (USAN/INN)
Zanamivir [USAN:INN:BAN]
Zanamivir hydrate
zanamivir
Show/Hide
|
||||||||||||||||||
Structure |
|
||||||||||||||||||
Formula |
C12H20N4O7
|
||||||||||||||||||
Molecular Weight |
332.313
|
||||||||||||||||||
Canonical SMILES |
CC(=O)N[C@@H]1[C@H](C=C(O[C@H]1[C@H](O)[C@H](O)CO)C(O)=O)N=C(N)N
Show/Hide
|
||||||||||||||||||
InChI |
InChI=1S/C12H20N4O7/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H2,1H3,(H,15,18)(H,21,22)(H4,13,14,16)/t5-,6+,8+,9+,10+/m0/s1
Show/Hide
|
||||||||||||||||||
InChIKey |
ARAIBEBZBOPLMB-UFGQHTETSA-N
|
||||||||||||||||||
CAS |
139110-80-8
|
||||||||||||||||||
Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
PubChem ID | |||||||||||||||||||
ChEMBL ID | |||||||||||||||||||
DrugBank ID |
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00018, Neuraminidase
Cell-based Assay
Biochemical Assays
Protein ID: PT02681, Neuraminidase
Clinical Information about the Compound
Drug 1 ( Zanamivir )
Drug Name | Zanamivir | ||
---|---|---|---|
Company | GlaxoSmithKline | ||
Indication | |||
Target(s) |
Influenza Neuraminidase (Influ NA)
Inhibitor
|